Plano Matthew T. - 01 Nov 2022 Form 4 Insider Report for ABIOMED INC

Role: VP, GLOBAL OPERATIONS
Signature: /s/ Marc A Began (by power of attorney)
Issuer symbol: N/A
Transactions as of: 01 Nov 2022
Net transactions value: -$929,158
Form type: 4
Filing time: 03 Nov 2022, 16:52:05 UTC
Previous filing: 12 Aug 2022
Next filing: 27 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NASD	Common Stock $.01 par value	Options Exercise	$412,648	+1,843	+15%	$223.90^*	13,814	01 Nov 2022	Direct	F1
transaction	NASD	Common Stock $.01 par value	Sale	$368,015	-974	-7.1%	$377.84^*	12,840	01 Nov 2022	Direct	F2, F3
transaction	NASD	Common Stock $.01 par value	Sale	$643,262	-1,699	-13%	$378.61^*	11,141	01 Nov 2022	Direct	F2, F4
transaction	NASD	Common Stock $.01 par value	Sale	$273,877	-722	-6.5%	$379.33^*	10,419	01 Nov 2022	Direct	F2, F5
transaction	NASD	Common Stock $.01 par value	Sale	$56,652	-149	-1.4%	$380.22^*	10,270	01 Nov 2022	Direct	F2, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NASD	Stock Option (Right to Buy)	Options Exercise	$0	-1,843	-67%	$0.000000	922	01 Nov 2022	Common Stock	0	$223.90	Direct	F1, F7, F8
holding	NASD	Stock Option (Right to Buy)						2,000	01 Nov 2022	Common Stock	0	$381.97	Direct	F7, F8
holding	NASD	Stock Option (Right to Buy)						5,000	01 Nov 2022	Common Stock	0	$266.39	Direct	F7, F8
holding	NASD	Stock Option (Right to Buy)						2,765	01 Nov 2022	Common Stock	0	$283.88	Direct	F7, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Exercise of stock options pursuant to reporting owners 10b5-1 plan.
F2	Sale of common stock pursuant to reporting owner's 10b5-1 plan.
F3	This price represents the sale price of the transactions on the reported date at $377.8389. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
F4	This price represents the sale price of the transactions on the reported date at $378.6120. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
F5	This price represents the sale price of the transactions on the reported date at $379.3305. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
F6	This price represents the sale price of the transactions on the reported date at $380.2151. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
F7	Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
F8	These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 2